CTMX (CytomX Therapeutics) Shiller PE Ratio: (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTMX CytomX Therapeutics Inc CTMX
38 GF Score
Price $3.42
GF Value $0.14
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is CytomX Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CytomX Therapeutics  (NAS:CTMX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CytomX Therapeutics Shiller PE Ratio Related Terms


CytomX Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Shiller PE Ratio Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CytomX Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CTMX vs BBOT, OMER, STTK: Shiller PE Ratio Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Shiller PE Ratio falls into.


CTMX
38GF Score
CytomX Therapeutics Inc CTMX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CytomX Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, CytomX Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.09/333.9520*333.9520
=-0.090

Current CPI (Jun. 2026) = 333.9520.

CytomX Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.400 241.428 -0.553
201612 -0.390 241.432 -0.539
201703 -0.230 243.801 -0.315
201706 -0.690 244.955 -0.941
201709 -0.280 246.819 -0.379
201712 0.030 246.524 0.041
201803 -0.400 249.554 -0.535
201806 -0.350 251.989 -0.464
201809 -0.530 252.439 -0.701
201812 -0.740 251.233 -0.984
201903 -0.310 254.202 -0.407
201906 -0.640 256.143 -0.834
201909 -0.520 256.759 -0.676
201912 -1.460 256.974 -1.897
202003 0.260 258.115 0.336
202006 -0.340 257.797 -0.440
202009 -0.320 260.280 -0.411
202012 -1.000 260.474 -1.282
202103 -0.260 264.877 -0.328
202106 -0.300 271.696 -0.369
202109 -0.350 274.310 -0.426
202112 -0.910 278.802 -1.090
202203 -0.490 287.504 -0.569
202206 -0.450 296.311 -0.507
202209 -0.440 296.808 -0.495
202212 -0.130 296.797 -0.146
202303 -0.050 301.836 -0.055
202306 -0.020 305.109 -0.022
202309 0.040 307.789 0.043
202312 0.010 306.746 0.011
202403 0.170 312.332 0.182
202406 -0.080 314.175 -0.085
202409 0.070 315.301 0.074
202412 0.230 315.605 0.243
202503 0.270 319.799 0.282
202506 0.000 322.561 0.000
202509 -0.090 324.800 -0.093
202512 -0.220 324.054 -0.227
202603 -0.100 330.213 -0.101
202606 -0.090 333.952 -0.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.42 is trading 2342.9% above its estimated GF Value™ of $0.14. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Shiller PE Ratio:
  • GF Value™: $0.14 vs. price of $3.42 (2342.9% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
38GF Score

Get the complete analysis for CTMX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.42
Price
$0.14
GF Value